NCT04036019

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy.

Detailed description

This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection. The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit.

Conditions

• B Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CD20-directed CAR-T cells with CliniMACS Prodigy® system	Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously

Timeline

• Start date: 2019-08-20
• Primary completion: 2022-06-20
• Completion: 2022-06-20
• First posted: 2019-07-29
• Last updated: 2024-05-28

Locations

1 site across 1 country: China